Suppr超能文献

结核合并HIV感染且未接受抗逆转录病毒治疗的患者中,对结核分枝杆菌抗原免疫重建增加的危险因素。

Risk factors for increased immune reconstitution in response to Mycobacterium tuberculosis antigens in tuberculosis HIV-infected, antiretroviral-naïve patients.

作者信息

da Silva Tatiana Pereira, Giacoia-Gripp Carmem Beatriz Wagner, Schmaltz Carolina A, Sant'Anna Flavia Marinho, Saad Maria Helena, Matos Juliana Arruda de, de Lima E Silva Julio Castro Alves, Rolla Valeria Cavalcanti, Morgado Mariza Gonçalves

机构信息

Laboratory of AIDS and Molecular Immunology, Oswaldo Cruz Institute, Fundação Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, Brazil.

Clinical Research Laboratory on Mycobacteria - National Institute of Infectious Diseases Evandro Chagas (FIOCRUZ), Rio de Janeiro, Brazil.

出版信息

BMC Infect Dis. 2017 Sep 6;17(1):606. doi: 10.1186/s12879-017-2700-6.

Abstract

BACKGROUND

Little is known regarding the restoration of the specific immune response after combined antiretroviral therapy (cART) and anti-tuberculosis (TB) therapy introduction among TB-HIV patients. In this study, we examined the immune response of TB-HIV patients to Mycobacterium tuberculosis (Mtb) antigens to evaluate the response dynamics to different antigens over time. Moreover, we also evaluated the influence of two different doses of efavirenz and the factors associated with immune reconstitution.

METHODS

This is a longitudinal study nested in a clinical trial, where cART was initiated during the baseline visit (D0), which occurred 30 ± 10 days after the introduction of anti-TB therapy. Follow-up visits were performed at 30, 60, 90 and 180 days after cART initiation. The production of IFN-γ upon in vitro stimulation with Mtb antigens purified protein derivative (PPD), ESAT-6 and 38 kDa/CFP-10 using ELISpot was examined at baseline and follow-up visits.

RESULTS

Sixty-one patients, all ART-naïve, were selected and included in the immune reconstitution analysis; seven (11.5%) developed Immune Reconstitution Inflammatory Syndrome (IRIS). The Mtb specific immune response was higher for the PPD antigen followed by 38 kDa/CFP-10 and increased in the first 60 days after cART initiation. In multivariate analysis, the variables independently associated with increased IFN-γ production in response to PPD antigen were CD4 T cell counts <200 cells/mm at baseline, age, site of tuberculosis, 800 mg efavirenz dose and follow-up CD4 T cell counts. Moreover, the factors associated with the production of IFN-γ in response to 38 kDa/CFP-10 were detectable HIV viral load (VL) and CD4 T cell counts at follow-up visits of ≥200 cells/mm.

CONCLUSIONS

These findings highlight the differences in immune response according to the specificity of the Mtb antigen, which contributes to a better understanding of TB-HIV immunopathogenesis. IFN-γ production elicited by PPD and 38 kDa/CFP-10 antigens have a greater magnitude compared to ESAT-6 and are associated with different factors. The low response to ESAT-6, even during immune restoration, suggests that this antigen is not adequate to assess the immune response of immunosuppressed TB-HIV patients.

摘要

背景

关于在合并抗逆转录病毒疗法(cART)和抗结核(TB)治疗引入后,结核合并艾滋病(TB-HIV)患者特异性免疫反应的恢复情况,人们了解甚少。在本研究中,我们检测了TB-HIV患者对结核分枝杆菌(Mtb)抗原的免疫反应,以评估不同抗原随时间变化的反应动态。此外,我们还评估了两种不同剂量依非韦伦的影响以及与免疫重建相关的因素。

方法

这是一项嵌套在临床试验中的纵向研究,在基线访视(D0)时启动cART,该访视在开始抗结核治疗后30±10天进行。在启动cART后的30、60、90和180天进行随访。在基线和随访时,使用酶联免疫斑点法(ELISpot)检测用Mtb抗原纯化蛋白衍生物(PPD)、早期分泌性抗原靶6(ESAT-6)和38 kDa/培养滤液蛋白10(CFP-10)体外刺激后干扰素-γ(IFN-γ)的产生。

结果

选择61例初治抗逆转录病毒治疗患者纳入免疫重建分析;7例(11.5%)发生免疫重建炎症综合征(IRIS)。PPD抗原的Mtb特异性免疫反应高于38 kDa/CFP-10,且在启动cART后的前60天增加。在多变量分析中,与PPD抗原刺激后IFN-γ产生增加独立相关的变量是基线时CD4 T细胞计数<200个细胞/mm³、年龄、结核病部位、800 mg依非韦伦剂量和随访时的CD4 T细胞计数。此外,与38 kDa/CFP-10刺激后IFN-γ产生相关的因素是随访时可检测到的HIV病毒载量(VL)和CD4 T细胞计数≥200个细胞/mm³。

结论

这些发现突出了根据Mtb抗原特异性的免疫反应差异,这有助于更好地理解TB-HIV免疫发病机制。与ESAT-6相比,PPD和38 kDa/CFP-10抗原引发的IFN-γ产生量更大,且与不同因素相关。即使在免疫恢复期间对ESAT-6的反应较低,这表明该抗原不足以评估免疫抑制的TB-HIV患者的免疫反应。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5236/5585929/cafc0908b381/12879_2017_2700_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验